中生北控生物科技股份有限公司 BIOSINO BIO-TECHNOLOGY AND SCIENCE INCORPORATION (a joint stock limited company incorporated in the People's Republic of China with limited liability) （於中華人民共和國註冊成立的股份有限公司） （Stobk Code 股份代號：8247） NOTIFICATION LETTER 通知信函 Dear Non-registered Shareholder(s) (Note 1) , 31 March 2026 Biosino Bio-Technology and Science Incorporation (the "Company") 各位非登記股東 （附註1） ： 中生北控生物科技股份有限公司（「本公司」） －2025年報及2025年度環境、社會及管治報告（「本次公司通訊」）之發佈通知 本公司的本次公司通訊之中、英文版本已分別上載於本公司網站(www.zhongsheng.com.cn )及 香 港 聯 合 交 易 所 有 限 公 ...

中生北控生物科技股份有限公司 BIOSINO BIO-TECHNOLOGY AND SCIENCE INCORPORATION (a joint stock limited company incorporated in the People's Republic of China with limited liability) （於中華人民共和國註冊成立的股份有限公司） （Stobk Code 股份代號：8247） NOTIFICATION LETTER 通知信函 Dear Registered Shareholders, 31 March 2026 Biosino Bio-Technology and Science Incorporation (the "Company") – Notice of publication of Annual Report 2025 and Environmental Social and Governance Report 2025 (the "Current Corporate Communication") The English and Chinese versi ...

BIOSINO BIO -TECHNO L OGY AND SCIENCE INCORPORATION 中生北控生物科技股份有限公司 環境、社會及管治报告 ENVIRONMENTAL SOCIAL AND 2025 GOVERNANCE REPORT | 目錄 | | | | | | | --- | --- | --- | --- | --- | --- | | | | | 03 | 環保政策與目標 應對氣候變化 | 24 24 | | | 關於本報告 | 1 | | | | | | | | 綠色低碳 | 低碳辦公 | 28 | | | 董事長致辭 | 2 | | 排放物管理與資源、能源使用 | 29 | | | 2025年度關鍵數據 | 3 | | | | | | 2025關鍵事件 | 5 | | | | | | 關於中生北控 | 7 | 04 | 企業文化與用人理念 | 31 | | | 公司榮譽 | 8 | | 人才培養與留任 | 31 | | | | | 人才發展 | 職業健康與安全 | 36 | | | 治理架構 | 9 | | | | | 01 | 董事會多元化 | 9 | | | | | | 董 ...

香港聯合交易所有限公司（「聯交所」）GEM的特色 GEM的定位，乃為相比起其他在聯交所上市的公司帶有較高投資風險的公司提供一個上市的市場。有意投資的人士 應了解投資於該等公司的潛在風險，並應經過審慎周詳的考慮後方作出投資決定。GEM的較高風險及其他特色表示 GEM較適合專業及其他老練投資者。 香港交易及結算所有限公司及聯交所對本報告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示 概不就因本報告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 本報告乃遵照聯交所 GEM證券上市規則（「《GEM上市規則》」）的規定提供有關中生北控生物科技股份有限公司（「本公 司」，與其附屬公司統稱為「本集團」）的資料，本公司各董事（「董事」）願就本報告共同及個別承擔全部責任。各董事經 作出一切合理查詢後確認，就彼等所深知及確信：(1) 本報告所載資料在各重大方面均屬準確完整，且無誤導或欺詐 成分；及(2) 本報告並無遺漏其他事項，致使本報告所載任何聲明或本報告產生誤導。 目 錄 | 頁次 | | | --- | --- | | 2 | 公司資料 | | 4 | 集團簡介 | | 5 | 財務 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示概不會就本公告全部或任何部分內容而產生 或因倚賴該等內容而引致之任何損失承擔任何責任。 中生北控生物科技股份有限公司 BIOSINO BIO-TECHNOLOGY AND SCIENCE INCORPORATION （於中華人民共和國註冊成立的股份有限公司） （股份代號：8247） 截至二零二五年十二月三十一日止年度的全年業績公告 香港聯合交易所有限公司（「聯交所」）GEM的特色 GEM的定位，乃為中小型公司提供一個上市的市場，此等公司相比起其他在聯交所上市 的公司帶有較高投資風險。有意投資的人士應了解投資於該等公司的潛在風險，並應經過 審慎周詳的考慮後方作出投資決定。 由於GEM上市公司普遍為中小型公司，在GEM買賣的證券可能會較於主板買賣之證券 承受較大的市場波動風險，同時無法保證在GEM買賣的證券會有高流通量的市場。 香港交易及結算所有限公司及聯交所對本公告之內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示概不會就本公告全部或任何部分內容而產生或因倚賴該等內容 而引致之任 ...

中生北控生物科技股份有限公司 BIOSINO BIO-TECHNOLOGY AND SCIENCE INCORPORATION （於中華人民共和國註冊成立的股份有限公司） （股份代號：8247） 香港交易及結算所有限公司及香港聯合交易所有限公司（「聯交所」）對本公佈之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示概不會就本公佈全部或任何部分內容而產生或因倚 賴該等內容而引致之任何損失承擔任何責任。 董渙樟 中國，北京，二零二六年三月十八日 – 1 – 1. 省覽及考慮本公司及其附屬公司（「本集團」）截至二零二五年十二月三十一日止 年度經審計財務報表連同董事會報告及核數師報告； 2. 批准於聯交所網站刊登本集團截至二零二五年十二月三十一日止年度之年度業 績公告； 3. 考慮本集團二零二五年年報之內容； 4. 考慮本公司二零二五年環境、社會及管治報告之內容； 5. 考慮截至二零二五年十二月三十一日止年度之本公司利潤分配預案以及派發末 期股息（如有）； 6. 考慮暫停辦理本公司過戶登記手續（如需要）；及 7. 處理任何其他事項。 於本公佈日期，董事會成員包括： 主席、總裁兼執行董事 陳鵬先生 副主席 ...

FF301 | RMB | | --- | | 本月底法定/註冊股本總額： 144,707,176 | | | 法定/註冊股份數目 | | 面值 | | 法定/註冊股本 | | --- | --- | --- | --- | --- | --- | | 上月底結存 | 80,421,033 | RMB | | 1 RMB | 80,421,033 | | 增加 / 減少 (-) | | 0 | | RMB | 0 | | 本月底結存 | 80,421,033 | RMB | | 1 RMB | 80,421,033 | I. 法定/註冊股本變動 1. 股份分類 普通股 股份類別 H 於香港聯交所上市 (註1) 是 證券代號 (如上市) 08247 說明 H股 法定/註冊股份數目 面值 法定/註冊股本 上月底結存 64,286,143 RMB 1 RMB 64,286,143 增加 / 減少 (-) 0 RMB 0 呈交日期: 2026年3月2日 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 第 1 頁 共 10 頁 v 1.2 ...

Core Viewpoint - The company has successfully obtained medical device registration for its BioCyte series flow cytometers in Malaysia, marking a significant step in expanding its market presence in Southeast Asia and serving global clinical and research users [1] Group 1: Product Development and Approval - The BioCyte series flow cytometers were developed by the company's subsidiary, Zhongsheng (Suzhou) Medical Technology Co., Ltd [1] - The registration number for the medical device is IVDA9463526–225393, indicating compliance with Malaysian regulatory standards [1] - The approval signifies that the product is now eligible for legal marketing, sales, and use in Malaysia [1] Group 2: Market Implications - The flow cytometry technology is widely used in clinical diagnostics and research, providing technical support for disease diagnosis, immunology research, and drug development [1] - The BioCyte series has already been applied in the domestic market due to its stable performance and accuracy in detection [1] - The company will collaborate with local authorized representative TRUSTDIAGNOSTICS SDN BHD to advance its market strategy in Malaysia [1]

Core Viewpoint - The company has successfully obtained medical device registration for its BioCyte series flow cytometers in Malaysia, marking a significant step in expanding its presence in the Southeast Asian market [1] Group 1: Product Development and Approval - The BioCyte series flow cytometers developed by the company's subsidiary, China Bio (Suzhou) Medical Technology Co., Ltd., have passed the Malaysian Medical Device Authority's review [1] - The registration number for the medical device is IVDA9463526–225393, indicating that the product is now legally qualified for sale and use in Malaysia [1] Group 2: Market Expansion and Strategy - The approval allows the company to expand its market reach in Southeast Asia and enhance its brand influence and market coverage internationally [1] - The product will be marketed through the local authorized representative, TRUST DIAGNOSTICS SDN BHD, facilitating the company's market entry strategy [1] Group 3: Technology Application - Flow cytometry technology is widely used in clinical diagnostics and research, providing technical support for disease diagnosis, immunology research, and drug development [1] - The BioCyte series has already been applied in the domestic market due to its stable performance and accuracy in detection [1]

Core Viewpoint - The company has successfully obtained medical device registration for its BioCyte series flow cytometers in Malaysia, marking a significant step in expanding its presence in the Southeast Asian market [1] Group 1: Product Development and Approval - The BioCyte series flow cytometers were developed by the company's subsidiary, Zhongsheng (Suzhou) Medical Technology Co., Ltd [1] - The registration number for the medical device is IVDA9463526–225393, indicating compliance with Malaysian regulatory standards [1] - The approval signifies that the product is now eligible for legal sales and use in Malaysia, enhancing the company's market opportunities [1] Group 2: Market Expansion and Strategy - The successful registration is expected to facilitate the company's expansion into the Southeast Asian market, aligning with its international development strategy [1] - The product will be marketed through a local authorized representative, TRUST DIAGNOSTICS SDN BHD, to enhance market penetration [1] - The flow cytometry technology is widely used in clinical diagnostics and research, providing support for disease diagnosis, immunology research, and drug development [1] Group 3: Regulatory Compliance - Malaysia has stringent regulatory standards for medical device approval, which the company successfully navigated by completing product testing and technical documentation submission [1] - The approval process underscores the company's commitment to meeting local regulatory requirements [1]